Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 19/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | STS | P08842 | 4/20 | 0.47 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3987586 | 0.87 | CYP19A1 (0.54) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Letrozole SCHEMBL29079510 | 0.84 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Letrozole SCHEMBL4331 | 0.84 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Letrozole SCHEMBL5326636 | 0.84 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Letrozole SCHEMBL178028 | 0.84 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Letrozole SCHEMBL1026263 | 0.83 | CYP19A1 (0.97) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Letrozole SCHEMBL28081077 | 0.83 | CYP19A1 (0.97) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL10075551 | 0.78 | CYP19A1 (0.85) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL13285157 | 0.78 | CYP19A1 (0.85) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL19661207 | 0.78 | CYP19A1 (0.85) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6696432-B1 | SYNERGYSTIC MIXTURES OF PRASTERONE, PREFERENTIAL ENZYME INHIBITORS SUCH AS FORMESTANE, TESTOLACTONE OR VOROZOLE AND CARRIERS, ADMINISTERED FOR PROPHYLAXIS OF HYPOANDROGENISM | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-02-24 | — | — | US | disclosed |
| EP-0885005-B1 | COMBINATION OF DEHYDROEPIANDROSTERONE AND AROMATASE INHIBITORS AND USE OF THIS COMBINATION TO PRODUCE A MEDICAMENT FOR TREATING RELATIVE AND ABSOLUTE ANDROGEN DEFICIENCY IN MEN | SCHERING AG (DE) | 2003-08-27 | — | — | EP | disclosed |
| EP-0782450-B1 | USE OF AROMATASE INHIBITORS IN THE PREPARATION OF A DRUG FOR TREATING A RELATIVE ANDROGEN DEFICIENCY IN MEN | SCHERING AG (DE) | 2003-06-04 | — | — | EP | disclosed |
| US-5906987-A | HORMONE REPLACEMENT THERAPY | SCHERING AKTIENGESELLSCHAFT AND BOARD OF REGENTS (DE) | 1999-05-25 | — | — | US | disclosed |
| US-5861389-A | TREATING MALE MENOPAUSE | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-01-19 | — | — | US | disclosed |
| EP-0885005-A2 | COMBINATION OF DEHYDROEPIANDROSTERONE AND AROMATASE INHIBITORS AND USE OF THIS COMBINATION TO PRODUCE A MEDICAMENT FOR TREATING RELATIVE AND ABSOLUTE ANDROGEN DEFICIENCY IN MEN | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997032588-A2 | COMBINATION OF DEHYDROEPIANDROSTERONE AND AROMATASE INHIBITORS AND USE OF THIS COMBINATION TO PRODUCE A MEDICAMENT FOR TREATING RELATIVE AND ABSOLUTE ANDROGEN DEFICIENCY IN MEN | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-09-12 | — | — | WO | disclosed |
| EP-0782450-A1 | USE OF AROMATASE INHIBITORS IN THE PREPARATION OF A DRUG FOR TREATING A RELATIVE ANDROGEN DEFICIENCY IN MEN | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-07-09 | — | — | EP | disclosed |
| WO-1996009057-A1 | USE OF AROMATASE INHIBITORS IN THE PREPARATION OF A DRUG FOR TREATING A RELATIVE ANDROGEN DEFICIENCY IN MEN | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-03-28 | — | — | WO | disclosed |